Sign up for our Oncology Central weekly news round-up

Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab for recurrent or advanced dMMR endometrial cancer patients


Abstract

This Plain Language Summary provides an outline of the GARNET trial which was published in JAMA Oncology in October 2020. The trial enrolled adult participants with advanced solid tumors. This report is restricted to patients with a particular type of endometrial cancer that has a deficient mismatch repair (dMMR) status. Patients received a trial treatment called dostarlimab (also known by the brand name Jemperli). In the US, dostarlimab is approved as a single therapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or after platinum-based chemotherapy. In the EU, dostarlimab is approved as a single therapy in adult patients with recurrent or advanced dMMR/microsatellite instability–high (MSI-H) endometrial cancer that has progressed on or after treatment with a platinum-containing regimen. The GARNET trial looked at dostarlimab given intravenously to patients with dMMR endometrial cancer from 7 countries. The trial showed that dostarlimab was successful in shrinking the tumor in 42% of these patients. In general, the percentage of participants who experienced medical problems (referred to as side effects) was low and within expectations for this type of treatment.

Read the original paper here

 

View the plain language summary that accompanies this paper below:

fon-2021-0598

Read the Plain Language summary here